Many drugs have reached the market through SBDD technology, such as captopril, an angiotensin-converting enzyme (ACE) inhibitor developed by Bristol Myers Squibb [37], which was the first to use enzyme-inhibitor structural information; saquinavir, which targets the human immunodeficiency virus protease, developed by Roche [38]; zanamivir, which is the neuraminidase inhibitor developed by Biota [39, 40]; and the most famous breakpoint cluster region-proto-oncogene tyrosine-protein kinase inhibitor, imatinib [41], developed by Novartis for the treatment of leukaemia. The gene discussed is ACE; the disease is leukemia.